Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review.
Alzheimer’s disease
Dementia
Quality of life
Systematic literature review
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
18 11 2020
18 11 2020
Historique:
received:
16
03
2020
accepted:
06
11
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
25
6
2021
Statut:
epublish
Résumé
Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer's disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is essential for economic evaluations of related health interventions. To provide an overview of which quality of life instruments are being used to assess HR-QoL in people with predementia AD, MCI or dementia; and, to summarise their reported HR-QoL levels at each stage of the disease and by type of respondent. We systematically searched for and reviewed eligible studies published between January 1990 and the end of April 2017 which reported HR-QoL for people with predementia AD, MCI or dementia. We only included instruments which are preference-based, allowing index scores/utility values to be attached to each health state they describe based on preferences obtained from population surveys. Summary results were presented by respondent type (self or proxy), type of instrument, geographical location and, where possible, stage of disease. Health state utility values derived using the EuroQoL 5-Dimensions (EQ-5D) were meta-analysed by pooling reported results across all studies by disease severity (MCI, mild, mild to moderate, moderate, severe dementia, not specified) and by respondent (person with dementia, carer, general public, not specified), using a fixed-effects approach. We identified 61 studies which reported HR-QoL for people with MCI or dementia using preference-based instruments, of which 48 used the EQ-5D. Thirty-six studies reported HR-QoL for mild and/or moderate disease severities, and 12 studies reported utility values for MCI. We found systematic differences between self-rated and proxy-rated HR-QoL, with proxy-rated utility valued being significantly lower in more severe disease states. A substantial literature now exists quantifying the impact of dementia on HR-QoL using preference-based measures, giving researchers and modellers a firmer basis on which to select appropriate utility values when estimating the effectiveness and cost-effectiveness of interventions in this area. Further research is required on HR-QoL of people with preclinical and prodromal AD and MCI, possible differences by type of dementia, the effects of comorbidities, study setting and the informal caregiver's own HR-QoL, including any effect of that on their proxy-ratings.
Sections du résumé
BACKGROUND
Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer's disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is essential for economic evaluations of related health interventions.
AIMS
To provide an overview of which quality of life instruments are being used to assess HR-QoL in people with predementia AD, MCI or dementia; and, to summarise their reported HR-QoL levels at each stage of the disease and by type of respondent.
METHODS
We systematically searched for and reviewed eligible studies published between January 1990 and the end of April 2017 which reported HR-QoL for people with predementia AD, MCI or dementia. We only included instruments which are preference-based, allowing index scores/utility values to be attached to each health state they describe based on preferences obtained from population surveys. Summary results were presented by respondent type (self or proxy), type of instrument, geographical location and, where possible, stage of disease. Health state utility values derived using the EuroQoL 5-Dimensions (EQ-5D) were meta-analysed by pooling reported results across all studies by disease severity (MCI, mild, mild to moderate, moderate, severe dementia, not specified) and by respondent (person with dementia, carer, general public, not specified), using a fixed-effects approach.
RESULTS
We identified 61 studies which reported HR-QoL for people with MCI or dementia using preference-based instruments, of which 48 used the EQ-5D. Thirty-six studies reported HR-QoL for mild and/or moderate disease severities, and 12 studies reported utility values for MCI. We found systematic differences between self-rated and proxy-rated HR-QoL, with proxy-rated utility valued being significantly lower in more severe disease states.
CONCLUSIONS
A substantial literature now exists quantifying the impact of dementia on HR-QoL using preference-based measures, giving researchers and modellers a firmer basis on which to select appropriate utility values when estimating the effectiveness and cost-effectiveness of interventions in this area. Further research is required on HR-QoL of people with preclinical and prodromal AD and MCI, possible differences by type of dementia, the effects of comorbidities, study setting and the informal caregiver's own HR-QoL, including any effect of that on their proxy-ratings.
Identifiants
pubmed: 33208190
doi: 10.1186/s13195-020-00723-1
pii: 10.1186/s13195-020-00723-1
pmc: PMC7677851
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
154Références
BMC Med Res Methodol. 2013 Sep 06;13:110
pubmed: 24011428
Lancet Neurol. 2008 Sep;7(9):812-26
pubmed: 18667359
Appl Health Econ Health Policy. 2017 Jun;15(3):399-412
pubmed: 27882528
Psychol Med. 2014 Mar;44(4):673-83
pubmed: 23521899
Alzheimers Dement. 2016 Mar;12(3):292-323
pubmed: 27012484
Value Health. 2011 Mar-Apr;14(2):390-9
pubmed: 21402307
Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):49-55
pubmed: 16493236
BMJ. 2011 Feb 10;342:d549
pubmed: 21310794
Pharmacoeconomics. 1996 Oct;10(4):336-55
pubmed: 10163577
Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S2
pubmed: 24565215
N Engl J Med. 2009 May 28;360(22):2302-9
pubmed: 19474427
Alzheimers Dement. 2017 Apr;13(4):374-380
pubmed: 28314660
Dement Neuropsychol. 2017 Oct-Dec;11(4):364-370
pubmed: 29354216
Neurology. 2000;54(11 Suppl 5):S4-9
pubmed: 10854354
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
BMJ Open. 2018 Mar 30;8(3):e019082
pubmed: 29602838
Pharmacoeconomics. 2016 Jul;34(7):645-9
pubmed: 26892973
J R Soc Interface. 2012 Jan 7;9(66):119-26
pubmed: 21653567
Alzheimers Dement. 2017 Jan;13(1):1-7
pubmed: 27583652
Dement Geriatr Cogn Disord. 2004;17(3):181-7
pubmed: 14739542
Biomed Res Int. 2014;2014:908915
pubmed: 25089278
Qual Life Res. 2018 May;27(5):1283-1294
pubmed: 29305782
J Alzheimers Dis. 2019;67(2):495-501
pubmed: 30584137
Drugs Aging. 2012 Jan 1;29(1):31-43
pubmed: 22191721
J Neurol Sci. 2002 Nov 15;203-204:29-34
pubmed: 12417353
Value Health. 2018 Apr;21(4):471-481
pubmed: 29680105